Renal tolerance with the use of intralipid-amphotericin B in low-birth- weight neonates

American Journal of Perinatology

Volumn 14, Issue 7, 1997, Pages 377-383

  Friedlich, Philippe S ^a   Steinberg, Irving ^a,b,c   Fujitani, Adrian ^a,c   DeLemos, Robert A ^a  

^a WOMEN S AND CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Amphotericin B; Fungal infection; Intralipid amphotericin B; Low birth weight infants; Nephrotoxicity

Indexed keywords

AMPHOTERICIN B; CREATININE; INTRALIPID; POTASSIUM;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; HUMAN; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NEPHROTOXICITY; NEWBORN; PRIORITY JOURNAL;

EID: 0030754017     PISSN: 07351631     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-994164     Document Type: Article

References (45)

1. Baley JE , Kliegman RM, Fanaroff AA. Disseminated fungal infections in the very low birth weight infants: Clinical manifestations and epidemiology. Pediatrics 1984;73:144-52
2. Miller MJ. Fungal infections. In Remington JS, Klein JO (eds): Infectious Diseases of the Fetus and Newborn Infant. Philadelphia: WB Saunders; 1995: pp 703-44
3. Faix RG. Invasive neonatal candidiasis: Comparison of albicans and parapsilosis infection. Pediatr Infect Dis J 1992;11: 88-93
4. Stamos JK, Rowley AH. Candidemia in a pediatric population. Clin Infect Dis 1995;20:571-5
5. Saxen H, Virtanen M, Carlson P, Hoppu K, Pohjavuori M, Vaara M, Vuopio-Varkila J, Peltola H. Neonatal Candida parapsilosis outbreak with a high case fatality rate. Pediatr Infect Disease J 1995;14:776-81
6. Weese-Mayer DE, Fondriest DW, Brouillette RT, Schulman ST. Risk factors associated with candidemia in the neonatal intensive care unit: A case control study. Pediatr Infect Dis J 1987;6:190-6
7. Pearse RG, Robertson NRC. Infection in the newborn. In Robertson NRC (ed): Texbook of Neonatology, 1st ed. Edisburgh: Churchill Livingstone; 1986: pp 725-81
8. Gustafson KS, Vercellotti BM, Bendel CM, Hostetter MK. Molecular mimicry in Candida albicans. J Clin Invest 1991; 87:1886-902
9. Ng PC, Thompson MA, Dear PRF. Dexamethasone and infection in preterm babies: A controlled study. Arch Dis Child 1990;65:54-8
10. Botas GM, Kurlat I, Young SM, Sola A. Disseminated candidal infections and intravenous hydrocortisone in preterm infants. Pediatrics 1995;95:883-7
11. Ramanathan R, Siassi B, Sardessai S, deLemos R. Dexamethasone versus hydrocrtisone for hypotension refractory to high dose inotropic agents and incidence of Candida infection in extremely low birthweight infants. Pediatr Res 1996; 39:240A
12. Rowen JL, Rench MA, Kozinetz CA, Adams, Jr. JM, Baker CJ. Endotracheal colonization with Candida enhances risk of systemic candidiasis in very low birth weight neonates. J Pediatr 1994;124:789-94
13. Reagan DR, Pfaller MA, Hollis RJ, Wenzel RP. Evidence of nosocomial spread of Candida albicans causing bloodstream infection in a neonatal intensive care unit. Diagn Microbiol Infect Dis 1995;21:191-4
14. Rowen JL, Atkins JT, Levy ML, Baer SC, Baker CJ. Invasive fungal dermatitis in the <1000-gram neonate. Pediatrics 1995;95:682-7
15. Van Den Anker JN, Van Popele NKL, Sauer PJJ. Antifungal agents in neonatal systemic candidiasis. Antimicrob Agents Chemother 1995;39:1391-7
16. Sawaya BP, Briggs JP, Schnermann J. Amphotericin B nephrotoxicity: The adverse consequences of altered membrane properties. J Am Soc Nephrol 1995;6:154-64
17. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: Recent progress and future directions. Clin Infect Dis 1996;22(Suppl 2):S133-44
18. Gates C, Pinney RJ. Amphotericin B and its delivery by liposomal and lipid formulations. J Clin Pharm Ther 1993;18: 147-53
19. Lackner H, Schwinger W, Urban C, Muller W, Ritchl E, Reiterer F, Kuttnig-Haim M, Urlesberger B, Hauer C. Liposomal amphotericin-B (AmBisome) for treament of disseminated fungal infections in two infants of very low birth weight. Pediatrics 1992;89:1259-61
20. daSilva LP, Amaral JMV, Ferreira NC. Which is the most appropriate dosage of liposomal amphotericin-B (AmBisome) for the treatment of fungal infections in infants of very low birth weight (letter). Pediatrics 1993;91:1217-8
21. Chavanet PY, Garry I, Charlier N, Caillot D, Kisterman JP, D'Athis M, Portier H. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. BMJ 1992;305:921-5
22. Pascual B, Ayestoran A, Montaro JB, Olivera J, Estibalez A, Julia A, Lopez A: Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia. Ann Pharmacother 1995;29:1997-200
23. Moreau P, Milpied N, Fayette N, Ramee JF, Harousseau J-L. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with Intralipid compared with conventional amphotericin B in neutropenic patients. J Antimicrob Chemother 1992;30:535-41
24. Caillot D, Chavanet P, Casanovas O, Solary E, Zanetta G, Buisson M, Wagner O, Cuisenier B, Bonnin A, Camerlynck P, Portier H, Guy H. Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B. Eur J Clin Microbiol Infect Dis 1992;11:722-5
25. Caillot D, Reny G, Solary E, Casasnovas O, Chavanet P, Bonnotte B, Perello L, Dumas M, Entezam F, Guy H. A controlled trial of the tolerance of amphotericin B infused in dextrose or in Lntralipid in patient with haematological malignancies. J Antimicrob Chemother 1994;33:603-13
26. Turner RB, Donowitz LG, Hendley JO. Consequences of candidemia for pediatric patients. AJDC 1985;139:178-80
27. Baley JE, Kliegman RM, Fanaroff AA. Disseminated fungal infections in the very low birth weight infants: Therapeutic toxicity. Pediatrics 1984;73:153-7
28. Baley JE, Meyers C, Kliegman RM, Jacobs MR, Blumer JL. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr 1990;116:791-7
29. Glick C, Graves GR, Feldmen S. Neonatal fungemia and amphotericin B. So Med J 1993;86:1368-71
30. Leibovitz E, Iustre-Reicher A, Amitai M, Mogilner B. Systemic candidal infections associated with use of peripheral venous catheters in neonates: A 9-Year Experience. Clin Infec Dis 1992;14:485-91
31. Butler KM, Rench MA, Baker CJ. Amphotericin B as a single agent in the treatment of systemic candidiasis in neonates. Pediatr Infect Dis J 1990;9:51-6
32. Caillot D, Casasnovas O, Solary E, Chavanet P , Bonnotte B, Reny G, Entezam F, Lopez J, Bonnin A, Guy H. Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients. J Antimicrob Chemother 1993;31:161-9
33. Macedo MCMA, Dulley FL, Ostronoff M, Machado CM, Zambon E, Matsumoto C, Dorlhiac-Llaccer P, Chamone DF. Effectiveness of amphotericin B in lipid emulsion for treating fungal septicemia in granulocytopenic patients Clin Infect Dis 1994;19:366-7
34. Anderson RP, Clark DA. Amphotericin B toxicity reduced by administration in fat emulsion. Ann Pharmacother 1995;29: 496-500
35. Leake HA, Appleyard MN, Hartley JPR. Successful treatment of resistant cryptococcal meningitis with amphotericin B lipid emulsion after nephrotoxicity with conventional intravenous amphotericin B. J Infect 1994;28:319-22
36. Joly V, Farinotti R, Saint-Julien L, Cheron M, Carbon C, Yeni P. In vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with Intralipid. Antimicrob Agents Chemother 1994;38:177-83
37. Kirsh R, Goldstein R, Tarloff J, Parris D, Hook J, Hanna N, Pugelski P, Poste G. An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. J Infect Dis 1988;158:1065-70
38. Wasan KM, Rosenblum MG, Cheung L, Lopez-Berenstein G. Influence of lipoproteins on the renal toxicity and antifungal activity of amphotericin B. Antimicrob Agents Chemother 1994;38:223-7
39. Lamb KA, Washington C, Davis SS, Denyer SP. Toxicity of amphotericin B emulsion to cultured canine kidney cell monolayers. J Pharm Pharmacol 1991;43:522-4
40. Forster D, Washington C, Davis SS. Toxicity of solubilized and colloidal amphotericin B formulations to human erythrocytes. J Pharm Phamacol 1988;40:325-8
41. Chavanet P, Caillot D. Lipid-based formulations of amphotericin B (correspondence reply). J Antimicrob Chemother 1995;35:711-3
42. Ayestaran A, Lopez RM, Montoro JB, Estibalez A, Pou L, Julia A, Lopez A, Pasqual B. Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia. Antimicrob Agents Chemother 1996;40:609-12
43. Cleary JD. Amphotericin B formulated in a lipid emulsion. Ann Pharmacother 1996;30:409-12
44. Trissel LA. Amphotericin B does not mix with fat emulsion. (Letter) Am J Health-Syst Pharm 1995;52:1463-4
45. Goff DA, Koletar SL, Buesching WJ, Barnishen J, Fass RJ. Isolation of fluconazole-resistant Candida albicans form human immunodeficiency virus-negative patients never treated with azoles. Clin Infect Dis 1995;20:77-83